IN2015DN00847A - - Google Patents
Info
- Publication number
- IN2015DN00847A IN2015DN00847A IN847DEN2015A IN2015DN00847A IN 2015DN00847 A IN2015DN00847 A IN 2015DN00847A IN 847DEN2015 A IN847DEN2015 A IN 847DEN2015A IN 2015DN00847 A IN2015DN00847 A IN 2015DN00847A
- Authority
- IN
- India
- Prior art keywords
- disclosed
- lfa
- polymorph
- formulations
- purification
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100341510 Mus musculus Itgal gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675663P | 2012-07-25 | 2012-07-25 | |
| US201261680099P | 2012-08-06 | 2012-08-06 | |
| US201261729294P | 2012-11-21 | 2012-11-21 | |
| PCT/US2013/052044 WO2014018748A1 (en) | 2012-07-25 | 2013-07-25 | Lfa-1 inhibitor and polymorph thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00847A true IN2015DN00847A (OSRAM) | 2015-06-12 |
Family
ID=49995472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN847DEN2015 IN2015DN00847A (OSRAM) | 2012-07-25 | 2013-07-25 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9085553B2 (OSRAM) |
| EP (3) | EP4406950A3 (OSRAM) |
| JP (3) | JP6607780B2 (OSRAM) |
| KR (2) | KR20200108932A (OSRAM) |
| CN (2) | CN110922393A (OSRAM) |
| AU (5) | AU2013295706A1 (OSRAM) |
| BR (1) | BR112015001608B1 (OSRAM) |
| CA (1) | CA2879982C (OSRAM) |
| HK (1) | HK1210782A1 (OSRAM) |
| IN (1) | IN2015DN00847A (OSRAM) |
| MX (2) | MX2015001098A (OSRAM) |
| RU (1) | RU2658015C2 (OSRAM) |
| SI (1) | SI3715345T1 (OSRAM) |
| WO (1) | WO2014018748A1 (OSRAM) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5794721B2 (ja) * | 2005-05-17 | 2015-10-14 | サーコード バイオサイエンス インコーポレイテッド | 眼障害の治療のための組成物および方法 |
| JP2011521896A (ja) * | 2008-04-15 | 2011-07-28 | サーコード コーポレイション | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
| EP4406950A3 (en) | 2012-07-25 | 2025-04-23 | Bausch + Lomb Ireland Limited | Lfa-1 inhibitor and polymorph thereof |
| JP6754356B2 (ja) * | 2014-09-25 | 2020-09-09 | ノバルティス アーゲー | 連続流のカルボキシル化反応 |
| EP3244851B1 (en) | 2015-01-12 | 2024-10-16 | Bausch + Lomb Ireland Limited | Micro-droplet delivery device |
| CA3016546A1 (en) | 2016-03-04 | 2017-09-08 | James M. Rynerson | Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation |
| CN107661302B (zh) * | 2016-07-29 | 2021-08-27 | 武汉朗来科技发展有限公司 | 一种口服固体制剂及其应用 |
| SG11201901137UA (en) | 2016-08-12 | 2019-03-28 | Silk Technologies Ltd | Silk-derived protein for treating inflammation |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| CA3039106A1 (en) | 2017-01-20 | 2018-07-26 | Kedalion Therapeutics, Inc. | Piezoelectric fluid dispenser |
| CN106947792A (zh) * | 2017-03-07 | 2017-07-14 | 上海倍殊生物科技有限公司 | 一种间甲砜基‑l‑苯丙氨酸的制备方法 |
| JP7232780B2 (ja) * | 2017-06-30 | 2023-03-03 | サイノファーム タイワン，リミティド | リフィテグラスト及びその中間体を調製するための方法 |
| US10723721B2 (en) * | 2017-07-24 | 2020-07-28 | Interquim, S.A. | Process for preparing and purifying the LFA-1 antagonist lifitegrast |
| WO2019026014A1 (en) * | 2017-08-03 | 2019-02-07 | Dr. Reddy's Laboratories Limited | METHODS FOR PREPARING LIFITEGRAST AND ITS INTERMEDIATES |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| EP3694499A4 (en) * | 2017-10-10 | 2021-09-01 | Mankind Pharma Ltd. | NEW PROCESS FOR MANUFACTURING LIFITEGRAST |
| WO2019097547A1 (en) | 2017-11-15 | 2019-05-23 | Cipla Limited | An improved process for the preparation of lifitegrast or salts thereof |
| WO2019096996A1 (en) | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| JP7436363B2 (ja) | 2017-12-08 | 2024-02-21 | ノバルティス アーゲー | 流体送達アライメントシステム |
| JP6914568B2 (ja) | 2018-01-15 | 2021-08-04 | コグニボティクス アクチエボラグＣｏｇｎｉｂｏｔｉｃｓ ＡＢ | 産業用ロボットアーム |
| US10435395B1 (en) | 2018-03-30 | 2019-10-08 | Scinopharm Taiwan, Ltd. | Crystal forms of lifitegrast |
| WO2019186520A1 (en) * | 2018-03-31 | 2019-10-03 | Aurobindo Pharma Limited | A process for the preparation of lifitegrast |
| US12350194B1 (en) | 2018-04-12 | 2025-07-08 | Bausch + Lomb Ireland Limited | Topical ocular delivery of fluids with controlled mass dosing and wireless communication |
| US20190314198A1 (en) | 2018-04-12 | 2019-10-17 | Kedalion Therapeutics, Inc. | Topical Ocular Delivery Methods and Devices for Use in the Same |
| IT201800006337A1 (it) | 2018-06-14 | 2019-12-14 | Procedimento per la preparazione di lifitegrast | |
| US12295881B2 (en) | 2018-07-03 | 2025-05-13 | Bausch + Lomb Ireland Limited | Topical ocular delivery devices and methods for using the same |
| CN111100118A (zh) * | 2018-10-29 | 2020-05-05 | 重庆圣华曦药业股份有限公司 | 一种立他司特杂质及其制备方法 |
| CN109384717A (zh) * | 2018-10-29 | 2019-02-26 | 广安凯特制药有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酸盐酸盐水合物及其制备方法和用途 |
| CN111285855A (zh) * | 2018-12-07 | 2020-06-16 | 苏州旺山旺水生物医药有限公司 | 一种制备化合物Lifitegrast的方法 |
| CN111471003B (zh) * | 2019-01-24 | 2022-09-23 | 上海皓元医药股份有限公司 | 一种立他司特中间体的制备方法 |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| US12097145B2 (en) | 2019-03-06 | 2024-09-24 | Bausch + Lomb Ireland Limited | Vented multi-dose ocular fluid delivery system |
| EP3955926A4 (en) * | 2019-04-18 | 2022-11-30 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN110256343A (zh) * | 2019-05-28 | 2019-09-20 | 苏州芝宇生物科技有限公司 | 3,5-二氯-4-溴异喹啉衍生物及其制备方法和应用 |
| CN112409256B (zh) * | 2019-08-21 | 2024-04-02 | 山东福长药业有限公司 | 5,7-二氯四氢异喹啉缩醛胺类化合物、其制备方法与应用 |
| US12496218B1 (en) | 2019-11-12 | 2025-12-16 | Bausch + Lomb Ireland Limited | Fractionated topical ocular drug delivery methods and devices for use in the same |
| CN111057003A (zh) * | 2019-12-06 | 2020-04-24 | 广安凯特制药有限公司 | 一种立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉的合成方法 |
| US12090087B2 (en) | 2020-04-17 | 2024-09-17 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| US11925577B2 (en) | 2020-04-17 | 2024-03-12 | Bausch + Lomb Ireland Limted | Hydrodynamically actuated preservative free dispensing system |
| US12290472B2 (en) | 2020-04-17 | 2025-05-06 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| CN111205275A (zh) * | 2020-04-22 | 2020-05-29 | 南京佰麦生物技术有限公司 | 立他司特晶型及其制备方法 |
| CN112321506B (zh) * | 2020-11-26 | 2021-12-24 | 江西天戌药业有限公司 | 一种5,7-二氯-1,2,3,4-四氢异喹啉的制备方法 |
| CN112500343B (zh) * | 2020-12-26 | 2023-04-07 | 山东金城柯瑞化学有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN112300139A (zh) * | 2020-12-29 | 2021-02-02 | 南京佰麦生物技术有限公司 | 立他司特水合物晶型及其制备方法 |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN119060022A (zh) * | 2021-09-18 | 2024-12-03 | 浙江大学医学院附属第一医院 | 立他司特的制备方法及其中间体化合物 |
| CN116063286A (zh) * | 2021-10-29 | 2023-05-05 | 威智医药有限公司 | 一种立他司特及其中间体的制备方法 |
| CN114524767B (zh) * | 2022-03-11 | 2022-10-18 | 成都道合尔医药技术有限公司 | 立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN115784950B (zh) * | 2022-12-08 | 2024-06-28 | 广东先强药业有限公司 | 一种立他司特中间体的制备方法 |
| CN116239532B (zh) * | 2022-12-19 | 2023-11-07 | 浙江博崤生物制药有限公司 | 一种二氯四氢异喹啉羧酸的中间体及其制备方法和应用 |
| CN116462644B (zh) * | 2023-05-06 | 2024-11-19 | 上海华默西医药科技有限公司 | 一种2-(呋喃-2-基亚甲基)-4-硝基丁酸酯化合物及其制备方法和应用 |
| WO2025186765A1 (en) * | 2024-03-08 | 2025-09-12 | Olon S.P.A. | Process for preparing lifitegrast |
| WO2025186758A1 (en) * | 2024-03-08 | 2025-09-12 | Olon S.P.A. | Process for preparing lifitegrast |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5759843A (en) * | 1980-09-30 | 1982-04-10 | Neos Co Ltd | Perfluoroalkyl ether amide derivative and its preparation |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| ATE114972T1 (de) | 1987-11-02 | 1994-12-15 | Baylor College Medicine | Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen. |
| ES2058351T3 (es) | 1988-01-29 | 1994-11-01 | Sumitomo Pharma | Un procedimiento para producir una formulacion de liberacion sostenida que es adecuada para el uso humano y veterinario. |
| DE3802996A1 (de) | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| ES2075016T3 (es) | 1988-08-23 | 1995-10-01 | Dana Farber Cancer Inst Inc | La subunidad alfa del receptor de adherencia a leucocitos lfa-1. |
| EP0362531B1 (en) | 1988-09-01 | 1999-11-10 | Bayer Corporation | A human rhinovirus receptor protein that inhibits virus infectivity |
| JP2976381B2 (ja) | 1988-09-28 | 1999-11-10 | ダナ ファーバー キャンサー インスティテュート | 細胞間粘着分子およびその結合性リガンド |
| US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| WO1990010652A1 (en) | 1989-03-09 | 1990-09-20 | Dana Farber Cancer Institute | Method of treating viral infections using lfa-1 |
| ZA903223B (en) | 1989-04-28 | 1991-02-27 | Baylor College Medicine | Dissemination of hiv-1 infected cells |
| CH679207A5 (OSRAM) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| WO1991019511A1 (en) | 1990-06-18 | 1991-12-26 | The General Hospital Corporation | CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5318965A (en) | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| WO1992003473A1 (en) | 1990-08-27 | 1992-03-05 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
| JP2995860B2 (ja) | 1990-11-27 | 1999-12-27 | 味の素株式会社 | 新規ペプチド |
| US5288854A (en) | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| DE69229275T2 (de) | 1991-10-04 | 1999-12-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5298492A (en) | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| JPH08500826A (ja) | 1992-08-21 | 1996-01-30 | ジェネンテク，インコーポレイテッド | Ｌｆａ−１仲介疾患を処置する方法 |
| WO1994011400A1 (en) | 1992-11-18 | 1994-05-26 | Helsinki University Licensing Ltd. Oy | Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis |
| RU2185393C2 (ru) | 1993-01-06 | 2002-07-20 | Кинертон Лимитед | Сложный полиэфир и конъюгат на его основе |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
| US5397791A (en) | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| SI0656348T1 (en) | 1993-12-03 | 2000-08-31 | F. Hoffmann-La Roche Ag | Aceric acid derivatives as medicaments |
| US5470953A (en) | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| JPH09512021A (ja) | 1994-04-19 | 1997-12-02 | ザ ユニバーシティ オブ カンサス | Ｉｃａｍ−１／ｌｆａ−１ 短鎖ペプチドおよび該ペプチドの使用方法 |
| US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5510495A (en) | 1994-09-19 | 1996-04-23 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis |
| US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ES2123889T3 (es) | 1994-11-02 | 1999-01-16 | Merck Patent Gmbh | Antagonistas de receptores de adhesion. |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| HUP0000732A3 (en) | 1996-04-23 | 2000-11-28 | Ipsen Mfg Ireland Ltd | Acidic polylactic polymers |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| JP2001527527A (ja) | 1996-11-27 | 2001-12-25 | デュポン ファーマシューティカルズ カンパニー | 新規インテグリン受容体拮抗薬 |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
| BR9909418A (pt) | 1998-03-27 | 2001-09-25 | Genentech Inc | Antagonistas para o tratamento de distúrbios mediados por receptor de aderência cd11/cd18 e método para tratar ou melhorar uma resposta ou distúrbio imunológico ou inflamatório em um mamìfero mediada através da famìlia cd11/cd18 em moléculas de aderência celular |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| ATE279914T1 (de) | 1998-11-27 | 2004-11-15 | Kanji Takada | Oral anzuwendendes arzneimittel zur wirkstoffverabreichung im magendarmtrakt |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| ATE330631T1 (de) | 1999-01-05 | 2006-07-15 | Univ Southern Australia | Antikörperfragmente zur lokalen behandlung von augenerkrankungen |
| WO2000044731A1 (en) | 1999-01-27 | 2000-08-03 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| AU776645B2 (en) | 1999-03-31 | 2004-09-16 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| US6645525B1 (en) | 1999-06-23 | 2003-11-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| ATE252915T1 (de) | 1999-08-18 | 2003-11-15 | Sod Conseils Rech Applic | Formulierung zur verzögerten freisetzung von peptiden |
| ECSP003707A (es) | 1999-10-13 | 2002-05-23 | Novartis Ag | Diazepanes |
| US6294522B1 (en) | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| CA2394862C (en) | 1999-12-14 | 2011-10-11 | Genentech, Inc. | Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| AU784226B2 (en) | 1999-12-31 | 2006-02-23 | Rutgers, The State University | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| WO2001049311A1 (en) | 1999-12-31 | 2001-07-12 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| US7521061B2 (en) | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| US20030064105A1 (en) | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| JP2003532703A (ja) | 2000-05-05 | 2003-11-05 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） | 新規アミノ酸誘導体及びその医薬としての使用 |
| GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| NZ523445A (en) | 2000-06-29 | 2004-10-29 | Abbott Lab | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| JP2002030052A (ja) * | 2000-07-18 | 2002-01-29 | Tosoh Corp | ヒドロキシアミノカルボン酸、その用途、及びその製造法 |
| WO2002026686A1 (en) * | 2000-09-27 | 2002-04-04 | Asahi Glass Company, Limited | Process for producing acyl fluoride and carboxylic acid salt |
| AR030817A1 (es) | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| GB0028367D0 (en) | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| CN1592746A (zh) | 2000-11-28 | 2005-03-09 | 杰南技术公司 | Lfa－1拮抗剂化合物 |
| US20030008848A1 (en) | 2000-12-19 | 2003-01-09 | Fleck Roman Wolfgang | Small molecules useful in the treatment of inflammatory disease |
| CA2435415A1 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| ES2275808T3 (es) | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
| US20030044406A1 (en) | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| AU2002258563A1 (en) | 2001-03-19 | 2002-10-03 | Praecis Pharmaceuticals Incorporated | Pharmaceutical formulations for sustained release |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| ES2296926T3 (es) | 2001-06-06 | 2008-05-01 | Aventis Pharma Limited | Tetrahidroisoquinolinas sustituidas para usar en el tratamiento de enfermedades inflamatorias. |
| KR20040066177A (ko) | 2001-12-19 | 2004-07-23 | 알자 코포레이션 | 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태 |
| RU2004129577A (ru) | 2002-03-04 | 2005-04-10 | Сосьете Де Консей Де Решерш Э Д`Аппликасьон (Fr) | Лекарственные композиции с замедленным высвобождением, содержащие пептид-носитель |
| PL374700A1 (pl) | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka |
| US7785578B2 (en) | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| RU2005117343A (ru) * | 2002-12-20 | 2006-01-27 | Астразенека Аб (Se) | Новые производные пиперидина в качестве модуляторов хемокинового рецептора ccr5 |
| US7459472B2 (en) | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| AU2004263508A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005042710A1 (en) | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| JP5105578B2 (ja) | 2003-11-05 | 2012-12-26 | サーコード バイオサイエンス インコーポレイテッド | 細胞接着のモジュレーター |
| GT200500139A (es) | 2004-06-08 | 2005-07-25 | Metodo para la preparacion de acidos hidroxamicos | |
| MX2007013469A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| JP5794721B2 (ja) | 2005-05-17 | 2015-10-14 | サーコード バイオサイエンス インコーポレイテッド | 眼障害の治療のための組成物および方法 |
| WO2007057919A2 (en) * | 2005-10-25 | 2007-05-24 | Alembic Limited | An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine |
| JP4193895B2 (ja) | 2006-10-12 | 2008-12-10 | 横河電機株式会社 | 欠陥検査装置 |
| AU2008317473B2 (en) | 2007-10-19 | 2014-07-17 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of diabetic retinopathy |
| CA2711043A1 (en) | 2008-01-01 | 2009-07-09 | Cipla Limited | Method of synthesis of bosentan, its polymorphic forms and its salts |
| US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP4406950A3 (en) * | 2012-07-25 | 2025-04-23 | Bausch + Lomb Ireland Limited | Lfa-1 inhibitor and polymorph thereof |
-
2013
- 2013-07-25 EP EP24169178.1A patent/EP4406950A3/en active Pending
- 2013-07-25 SI SI201332083T patent/SI3715345T1/sl unknown
- 2013-07-25 CN CN201911035155.8A patent/CN110922393A/zh active Pending
- 2013-07-25 CN CN201380048592.8A patent/CN104797574B/zh active Active
- 2013-07-25 AU AU2013295706A patent/AU2013295706A1/en not_active Abandoned
- 2013-07-25 EP EP20153723.0A patent/EP3715345B8/en active Active
- 2013-07-25 MX MX2015001098A patent/MX2015001098A/es active IP Right Grant
- 2013-07-25 KR KR1020207026445A patent/KR20200108932A/ko not_active Ceased
- 2013-07-25 EP EP13823367.1A patent/EP2877465A4/en not_active Withdrawn
- 2013-07-25 BR BR112015001608-1A patent/BR112015001608B1/pt active IP Right Grant
- 2013-07-25 HK HK15111648.6A patent/HK1210782A1/xx unknown
- 2013-07-25 US US13/950,807 patent/US9085553B2/en active Active
- 2013-07-25 RU RU2015102926A patent/RU2658015C2/ru active
- 2013-07-25 WO PCT/US2013/052044 patent/WO2014018748A1/en not_active Ceased
- 2013-07-25 IN IN847DEN2015 patent/IN2015DN00847A/en unknown
- 2013-07-25 KR KR1020157004283A patent/KR102157608B1/ko active Active
- 2013-07-25 CA CA2879982A patent/CA2879982C/en active Active
- 2013-07-25 JP JP2015524447A patent/JP6607780B2/ja active Active
-
2015
- 2015-01-23 MX MX2020001602A patent/MX2020001602A/es unknown
- 2015-06-23 US US14/747,745 patent/US9708303B2/en active Active
-
2017
- 2017-06-13 US US15/621,141 patent/US10214517B2/en active Active
- 2017-11-22 AU AU2017265071A patent/AU2017265071B2/en active Active
-
2018
- 2018-07-19 JP JP2018135758A patent/JP2018162313A/ja active Pending
-
2019
- 2019-01-15 US US16/247,843 patent/US10906892B2/en active Active
- 2019-07-30 AU AU2019210525A patent/AU2019210525B2/en active Active
-
2020
- 2020-06-03 JP JP2020096854A patent/JP7008750B2/ja active Active
- 2020-12-02 AU AU2020281063A patent/AU2020281063A1/en not_active Abandoned
-
2023
- 2023-07-04 AU AU2023204287A patent/AU2023204287B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00847A (OSRAM) | ||
| IL274469A (en) | Compositions, uses and methods for the treatment of metabolic disorders and diseases | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| HUE037600T2 (hu) | Vegyületek és készítmények paraziták által okozott fertõzések kezelésére | |
| ZA201402424B (en) | 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| EP2938616A4 (en) | PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF | |
| IN2015DN01119A (OSRAM) | ||
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| PL2892556T3 (pl) | Kompozycje i sposoby odnoszące się do leczenia chorób | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| PL395469A1 (pl) | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego | |
| GB201217331D0 (en) | Novel compound useful for the treatment of infectious diseases | |
| AU2011900644A0 (en) | Therapeutic Uses of SLIRP | |
| HK1182092A (en) | Arylosulfonamides for the treatment of cns diseases | |
| AU2011903764A0 (en) | Treatment of bone diseases |